Can you take Dyclonine / menthol topical with Enfortumab vedotin?

Enfortumab vedotin has a moderate potential interaction with Diabetes Mellitus.

Hyperglycemia occurred in patients treated with enfortumab vedotin, including death, and diabetic ketoacidosis (DKA) in those with and without preexisting-existing diabetes mellitus. The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold treatment.

The dyclonine topical in dyclonine / menthol topical has a moderate potential interaction with Heart Block.

Dyclonine is absorbed rapidly through intact skin and mucosal membranes following topical administration. Prolonged exposure, large doses, frequent applications and/or use on compromised skin or mucosa can produce systemic toxicity. Cardiovascular adverse effects include depression of myocardium, hypotension, bradycardia, and cardiac arrest. Therapy with dyclonine topical should be administered cautiously in patients with shock, sinus bradyarrhythmia, or severe heart block. The recommended dosage should not be exceeded.

Enfortumab vedotin has a major potential interaction with Liver Disease.

Avoid the use of enfortumab vedotin in patients with moderate or severe hepatic impairment as it has not been studied in these patients. No adjustment in the starting dose is required when treating patients with mild hepatic impairment.

Enfortumab vedotin has a moderate potential interaction with Peripheral Neuropathy.

Peripheral neuropathy, predominantly sensory, occurred in 49% of the patients treated with enfortumab vedotin in clinical trials. Peripheral neuropathy occurred in patients with or without preexisting peripheral neuropathy. Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction when peripheral neuropathy occurs. Permanently discontinue treatment in patients that develop Grade >3 peripheral neuropathy.

The dyclonine topical in dyclonine / menthol topical has a moderate potential interaction with Shock.

Dyclonine is absorbed rapidly through intact skin and mucosal membranes following topical administration. Prolonged exposure, large doses, frequent applications and/or use on compromised skin or mucosa can produce systemic toxicity. Cardiovascular adverse effects include depression of myocardium, hypotension, bradycardia, and cardiac arrest. Therapy with dyclonine topical should be administered cautiously in patients with shock, sinus bradyarrhythmia, or severe heart block. The recommended dosage should not be exceeded.